G1 Therapeutics buy michaelkr
Start price
02.05.23
/
50%
€2.66
Target price
02.05.24
-
Performance (%)
0.00%
End price
14.05.23
€2.66
Summary
This prediction ended on 14.05.23 with a price of €2.66. michaelkr's BUY prediction for G1 Therapeutics closed unchanged from the start price. michaelkr has 50% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| G1 Therapeutics | -5.263% | -5.263% | 35.172% |
| iShares Core DAX® | -0.992% | -3.231% | 11.661% |
| iShares Nasdaq 100 | -0.225% | -3.339% | 36.491% |
| iShares Nikkei 225® | -0.736% | -7.859% | 18.597% |
| iShares S&P 500 | -0.509% | -2.979% | 26.341% |
According to michaelkr what are the pros and cons of G1 Therapeutics for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by michaelkr for this prediction
In the thread G1 Therapeutics diskutieren
Buy G1 Therapeutics
In the thread Trading G1 Therapeutics
Stopped prediction by michaelkr for G1 Therapeutics
G1 Therapeutics
Start price
Target price
Perf. (%)
€3.38
22.01.24
22.01.24
-
22.01.25
22.01.25
14.50%
03.02.24
03.02.24
Could be very worthwhile Investment >20% year
